Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.58 |
| ▸ | EGFR | P00533 | 15/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 5/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684248 | 0.89 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL2748644 | 0.88 | EGFR (0.72) | ERBB2EGFRERBB3ERBB4LCK | |
| Hydrochloric Acid SCHEMBL2747544 | 0.86 | ERBB2 (0.59) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL2749495 | 0.86 | EGFR (0.69) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL3899290 | 0.85 | ERBB2 (0.54) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL27684223 | 0.85 | ERBB2 (0.62) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL2749966 | 0.85 | ERBB2 (0.59) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL2747553 | 0.83 | ERBB2 (0.53) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL27664602 | 0.82 | ERBB2 (0.62) | ERBB2EGFRERBB3ERBB4LCK | |
| SCHEMBL4763459 | 0.81 | ERBB2 (0.56) | ERBB2EGFRERBB3ERBB4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | ERBB2 21/4885EGFR 68/4885ERBB3 2/4885 |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | ERBB2 21/4885EGFR 68/4885ERBB3 2/4885 |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | ERBB2 21/4885EGFR 68/4885ERBB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.